Sodium/glucose co-transporter 2 inhibitors (SGLT2i) lower blood glucose by inhibiting the reabsorption of glucose in the proximal renal tubules.[1] There are several licensed SGLT2i. One of them, e...
No takes yet. Share an insight, caveat, or question.
Athyros et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: